104 related articles for article (PubMed ID: 22890856)
1. Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Int J Cancer; 2013 Jan; 132(2):E66-73. PubMed ID: 22890856
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for advanced gastric cancer.
Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.
Yang L; Jiang X; Yan H; Li Y; Zhen H; Chang B; Kariminia S; Li Q
BMC Gastroenterol; 2018 Apr; 18(1):43. PubMed ID: 29609559
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Cho YH; Yoon SY; Kim SN
Cancer Res Treat; 2017 Jan; 49(1):255-262. PubMed ID: 27188198
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Wang DL; Gu DY; Huang HY; Xu Z; Chen JF
World J Gastroenterol; 2010 Dec; 16(46):5889-94. PubMed ID: 21155012
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer.
Nishikawa K; Koizumi W; Tsuburaya A; Yamanaka T; Morita S; Fujitani K; Akamaru Y; Shimada K; Hosaka H; Nakayama N; Tsujinaka T; Sakamoto J
Gastric Cancer; 2020 Jan; 23(1):160-167. PubMed ID: 31309387
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Xu F; Ren X; Chen Y; Li Q; Li R; Chen Y; Xia S
BMC Cancer; 2018 Aug; 18(1):808. PubMed ID: 30097029
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Zeng C; Zhou H; Wei Y; Wang L; Xie H; Yao W
Chin Med J (Engl); 2014; 127(5):951-6. PubMed ID: 24571893
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
11. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
Wagner AD; Grothe W; Haerting J; Kleber G; Grothey A; Fleig WE
J Clin Oncol; 2006 Jun; 24(18):2903-9. PubMed ID: 16782930
[TBL] [Abstract][Full Text] [Related]
13. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Goto A; Sukawa Y; Igarashi H; Onodera K; Aoki Y; Suzuki K; Yonezawa K; Yawata A; Kobayashi T; Kaneto H; Shimizu H; Wakasugi H; Matsunaga Y; Itoh M; Okuda H; Arimura Y; Shinomura Y
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1461-6. PubMed ID: 21945893
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.
Chen WW; Wang F; Xu RH
PLoS One; 2013; 8(7):e68974. PubMed ID: 23874831
[TBL] [Abstract][Full Text] [Related]
17. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Kim HS; Kim HJ; Kim SY; Kim TY; Lee KW; Baek SK; Kim TY; Ryu MH; Nam BH; Zang DY
Ann Oncol; 2013 Nov; 24(11):2850-4. PubMed ID: 23942775
[TBL] [Abstract][Full Text] [Related]
20. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
